Open access
Sep 2026
Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study.
BACKGROUND Individually, sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP-1RA and SGLT2i therapy in this p...
Hussain Salim, Shaheer Qureshi, G. Gulsin et al.
· Diabetes, obesity and metabo... · 0 citations